IBDEI1G6 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,23412,1,4,0)
;;=4^D68.318
;;^UTILITY(U,$J,358.3,23412,2)
;;=^340504
;;^UTILITY(U,$J,358.3,23413,0)
;;=Z79.01^^78^1009^14
;;^UTILITY(U,$J,358.3,23413,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23413,1,3,0)
;;=3^Long Term (Current) Use of Anticoagulants
;;^UTILITY(U,$J,358.3,23413,1,4,0)
;;=4^Z79.01
;;^UTILITY(U,$J,358.3,23413,2)
;;=^5063330
;;^UTILITY(U,$J,358.3,23414,0)
;;=Z79.02^^78^1009^15
;;^UTILITY(U,$J,358.3,23414,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23414,1,3,0)
;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
;;^UTILITY(U,$J,358.3,23414,1,4,0)
;;=4^Z79.02
;;^UTILITY(U,$J,358.3,23414,2)
;;=^5063331
;;^UTILITY(U,$J,358.3,23415,0)
;;=D68.62^^78^1009^16
;;^UTILITY(U,$J,358.3,23415,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23415,1,3,0)
;;=3^Lupus Anticoagulant Syndrome
;;^UTILITY(U,$J,358.3,23415,1,4,0)
;;=4^D68.62
;;^UTILITY(U,$J,358.3,23415,2)
;;=^5002361
;;^UTILITY(U,$J,358.3,23416,0)
;;=I73.9^^78^1009^17
;;^UTILITY(U,$J,358.3,23416,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23416,1,3,0)
;;=3^Peripheral Vascular Disease,Unspec
;;^UTILITY(U,$J,358.3,23416,1,4,0)
;;=4^I73.9
;;^UTILITY(U,$J,358.3,23416,2)
;;=^184182
;;^UTILITY(U,$J,358.3,23417,0)
;;=Z86.79^^78^1009^18
;;^UTILITY(U,$J,358.3,23417,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23417,1,3,0)
;;=3^Personal Hx of Circulatory System Diseases
;;^UTILITY(U,$J,358.3,23417,1,4,0)
;;=4^Z86.79
;;^UTILITY(U,$J,358.3,23417,2)
;;=^5063479
;;^UTILITY(U,$J,358.3,23418,0)
;;=Z86.711^^78^1009^19
;;^UTILITY(U,$J,358.3,23418,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23418,1,3,0)
;;=3^Personal Hx of Pulmonary Embolism
;;^UTILITY(U,$J,358.3,23418,1,4,0)
;;=4^Z86.711
;;^UTILITY(U,$J,358.3,23418,2)
;;=^5063474
;;^UTILITY(U,$J,358.3,23419,0)
;;=Z86.718^^78^1009^20
;;^UTILITY(U,$J,358.3,23419,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23419,1,3,0)
;;=3^Personal Hx of Venous Thrombosis/Embolism
;;^UTILITY(U,$J,358.3,23419,1,4,0)
;;=4^Z86.718
;;^UTILITY(U,$J,358.3,23419,2)
;;=^5063475
;;^UTILITY(U,$J,358.3,23420,0)
;;=Z95.2^^78^1009^21
;;^UTILITY(U,$J,358.3,23420,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23420,1,3,0)
;;=3^Presence of Prosthetic Heart Valve
;;^UTILITY(U,$J,358.3,23420,1,4,0)
;;=4^Z95.2
;;^UTILITY(U,$J,358.3,23420,2)
;;=^5063670
;;^UTILITY(U,$J,358.3,23421,0)
;;=D68.59^^78^1009^22
;;^UTILITY(U,$J,358.3,23421,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23421,1,3,0)
;;=3^Primary Thrombophilia
;;^UTILITY(U,$J,358.3,23421,1,4,0)
;;=4^D68.59
;;^UTILITY(U,$J,358.3,23421,2)
;;=^5002360
;;^UTILITY(U,$J,358.3,23422,0)
;;=I26.99^^78^1009^23
;;^UTILITY(U,$J,358.3,23422,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23422,1,3,0)
;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
;;^UTILITY(U,$J,358.3,23422,1,4,0)
;;=4^I26.99
;;^UTILITY(U,$J,358.3,23422,2)
;;=^5007150
;;^UTILITY(U,$J,358.3,23423,0)
;;=I42.5^^78^1009^24
;;^UTILITY(U,$J,358.3,23423,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23423,1,3,0)
;;=3^Restrictive Cardiomyopathy
;;^UTILITY(U,$J,358.3,23423,1,4,0)
;;=4^I42.5
;;^UTILITY(U,$J,358.3,23423,2)
;;=^5007196
;;^UTILITY(U,$J,358.3,23424,0)
;;=G45.9^^78^1009^26
;;^UTILITY(U,$J,358.3,23424,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,23424,1,3,0)
;;=3^Transient Cerebral Ischemic Attack,Unspec
;;^UTILITY(U,$J,358.3,23424,1,4,0)
;;=4^G45.9
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1G6 3789 printed Apr 09, 2024@21:39:57 Page 2
IBDEI1G6 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,23412,1,4,0)
+2 ;;=4^D68.318
+3 ;;^UTILITY(U,$J,358.3,23412,2)
+4 ;;=^340504
+5 ;;^UTILITY(U,$J,358.3,23413,0)
+6 ;;=Z79.01^^78^1009^14
+7 ;;^UTILITY(U,$J,358.3,23413,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,23413,1,3,0)
+10 ;;=3^Long Term (Current) Use of Anticoagulants
+11 ;;^UTILITY(U,$J,358.3,23413,1,4,0)
+12 ;;=4^Z79.01
+13 ;;^UTILITY(U,$J,358.3,23413,2)
+14 ;;=^5063330
+15 ;;^UTILITY(U,$J,358.3,23414,0)
+16 ;;=Z79.02^^78^1009^15
+17 ;;^UTILITY(U,$J,358.3,23414,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,23414,1,3,0)
+20 ;;=3^Long Term (Current) use of Antithrombotics/Antiplatelets
+21 ;;^UTILITY(U,$J,358.3,23414,1,4,0)
+22 ;;=4^Z79.02
+23 ;;^UTILITY(U,$J,358.3,23414,2)
+24 ;;=^5063331
+25 ;;^UTILITY(U,$J,358.3,23415,0)
+26 ;;=D68.62^^78^1009^16
+27 ;;^UTILITY(U,$J,358.3,23415,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,23415,1,3,0)
+30 ;;=3^Lupus Anticoagulant Syndrome
+31 ;;^UTILITY(U,$J,358.3,23415,1,4,0)
+32 ;;=4^D68.62
+33 ;;^UTILITY(U,$J,358.3,23415,2)
+34 ;;=^5002361
+35 ;;^UTILITY(U,$J,358.3,23416,0)
+36 ;;=I73.9^^78^1009^17
+37 ;;^UTILITY(U,$J,358.3,23416,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,23416,1,3,0)
+40 ;;=3^Peripheral Vascular Disease,Unspec
+41 ;;^UTILITY(U,$J,358.3,23416,1,4,0)
+42 ;;=4^I73.9
+43 ;;^UTILITY(U,$J,358.3,23416,2)
+44 ;;=^184182
+45 ;;^UTILITY(U,$J,358.3,23417,0)
+46 ;;=Z86.79^^78^1009^18
+47 ;;^UTILITY(U,$J,358.3,23417,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,23417,1,3,0)
+50 ;;=3^Personal Hx of Circulatory System Diseases
+51 ;;^UTILITY(U,$J,358.3,23417,1,4,0)
+52 ;;=4^Z86.79
+53 ;;^UTILITY(U,$J,358.3,23417,2)
+54 ;;=^5063479
+55 ;;^UTILITY(U,$J,358.3,23418,0)
+56 ;;=Z86.711^^78^1009^19
+57 ;;^UTILITY(U,$J,358.3,23418,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,23418,1,3,0)
+60 ;;=3^Personal Hx of Pulmonary Embolism
+61 ;;^UTILITY(U,$J,358.3,23418,1,4,0)
+62 ;;=4^Z86.711
+63 ;;^UTILITY(U,$J,358.3,23418,2)
+64 ;;=^5063474
+65 ;;^UTILITY(U,$J,358.3,23419,0)
+66 ;;=Z86.718^^78^1009^20
+67 ;;^UTILITY(U,$J,358.3,23419,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,23419,1,3,0)
+70 ;;=3^Personal Hx of Venous Thrombosis/Embolism
+71 ;;^UTILITY(U,$J,358.3,23419,1,4,0)
+72 ;;=4^Z86.718
+73 ;;^UTILITY(U,$J,358.3,23419,2)
+74 ;;=^5063475
+75 ;;^UTILITY(U,$J,358.3,23420,0)
+76 ;;=Z95.2^^78^1009^21
+77 ;;^UTILITY(U,$J,358.3,23420,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,23420,1,3,0)
+80 ;;=3^Presence of Prosthetic Heart Valve
+81 ;;^UTILITY(U,$J,358.3,23420,1,4,0)
+82 ;;=4^Z95.2
+83 ;;^UTILITY(U,$J,358.3,23420,2)
+84 ;;=^5063670
+85 ;;^UTILITY(U,$J,358.3,23421,0)
+86 ;;=D68.59^^78^1009^22
+87 ;;^UTILITY(U,$J,358.3,23421,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,23421,1,3,0)
+90 ;;=3^Primary Thrombophilia
+91 ;;^UTILITY(U,$J,358.3,23421,1,4,0)
+92 ;;=4^D68.59
+93 ;;^UTILITY(U,$J,358.3,23421,2)
+94 ;;=^5002360
+95 ;;^UTILITY(U,$J,358.3,23422,0)
+96 ;;=I26.99^^78^1009^23
+97 ;;^UTILITY(U,$J,358.3,23422,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,23422,1,3,0)
+100 ;;=3^Pulmonary Embolism w/o Acute Cor Pulmonale
+101 ;;^UTILITY(U,$J,358.3,23422,1,4,0)
+102 ;;=4^I26.99
+103 ;;^UTILITY(U,$J,358.3,23422,2)
+104 ;;=^5007150
+105 ;;^UTILITY(U,$J,358.3,23423,0)
+106 ;;=I42.5^^78^1009^24
+107 ;;^UTILITY(U,$J,358.3,23423,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,23423,1,3,0)
+110 ;;=3^Restrictive Cardiomyopathy
+111 ;;^UTILITY(U,$J,358.3,23423,1,4,0)
+112 ;;=4^I42.5
+113 ;;^UTILITY(U,$J,358.3,23423,2)
+114 ;;=^5007196
+115 ;;^UTILITY(U,$J,358.3,23424,0)
+116 ;;=G45.9^^78^1009^26
+117 ;;^UTILITY(U,$J,358.3,23424,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,23424,1,3,0)
+120 ;;=3^Transient Cerebral Ischemic Attack,Unspec
+121 ;;^UTILITY(U,$J,358.3,23424,1,4,0)
+122 ;;=4^G45.9
